The global lipase inhibitors obesity drugs market size is calculated at USD 1.43 billion in 2025 and is forecasted to reach around USD 4.94 billion by 2034, accelerating at a CAGR of 14.72% from 2025 to 2034. The North America market size surpassed USD 487.50 million in 2024 and is expanding at a CAGR of 14.88% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Lipase Inhibitors Obesity Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Lipase Inhibitors Obesity Drugs Market Revenue and Volume, by Drug Type
8.1.1. Orlistat (Xenical, Alli)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Cetilistat
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Experimental/Investigational Lipase Inhibitors
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Others (Modified-release or combination therapies)
8.1.4.1. Market Revenue and Volume Forecast
9.1. Lipase Inhibitors Obesity Drugs Market Revenue and Volume, by Formulation
9.1.1. Capsules
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Tablets
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Powder
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Soft Gels
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Others (e.g., Oral disintegrating films, patches under development)
9.1.5.1. Market Revenue and Volume Forecast
10.1. Lipase Inhibitors Obesity Drugs Market Revenue and Volume, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Transdermal (investigational)
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Others (Buccal/sublingual – exploratory)
10.1.3.1. Market Revenue and Volume Forecast
11.1. Lipase Inhibitors Obesity Drugs Market Revenue and Volume, by Distribution Channel
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Volume Forecast
12.1. Lipase Inhibitors Obesity Drugs Market Revenue and Volume, by Patient Group
12.1.1. Adults
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Pediatric/Adolescent (limited approval)
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Others (High-risk/metabolic syndrome patients)
12.1.3.1. Market Revenue and Volume Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Drug Type
13.1.2. Market Revenue and Volume Forecast, by Formulation
13.1.3. Market Revenue and Volume Forecast, by Route of Administration
13.1.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1.5. Market Revenue and Volume Forecast, by Patient Group
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Drug Type
13.1.6.2. Market Revenue and Volume Forecast, by Formulation
13.1.6.3. Market Revenue and Volume Forecast, by Route of Administration
13.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1.6.5. Market Revenue and Volume Forecast, by Patient Group
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Drug Type
13.1.7.2. Market Revenue and Volume Forecast, by Formulation
13.1.7.3. Market Revenue and Volume Forecast, by Route of Administration
13.1.7.4. Market Revenue and Volume Forecast, by Distribution Channel
13.1.7.5. Market Revenue and Volume Forecast, by Patient Group
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Drug Type
13.2.2. Market Revenue and Volume Forecast, by Formulation
13.2.3. Market Revenue and Volume Forecast, by Route of Administration
13.2.4. Market Revenue and Volume Forecast, by Distribution Channel
13.2.5. Market Revenue and Volume Forecast, by Patient Group
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Drug Type
13.2.6.2. Market Revenue and Volume Forecast, by Formulation
13.2.6.3. Market Revenue and Volume Forecast, by Route of Administration
13.2.7. Market Revenue and Volume Forecast, by Distribution Channel
13.2.8. Market Revenue and Volume Forecast, by Patient Group
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Drug Type
13.2.9.2. Market Revenue and Volume Forecast, by Formulation
13.2.9.3. Market Revenue and Volume Forecast, by Route of Administration
13.2.10. Market Revenue and Volume Forecast, by Distribution Channel
13.2.11. Market Revenue and Volume Forecast, by Patient Group
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Drug Type
13.2.12.2. Market Revenue and Volume Forecast, by Formulation
13.2.12.3. Market Revenue and Volume Forecast, by Route of Administration
13.2.12.4. Market Revenue and Volume Forecast, by Distribution Channel
13.2.13. Market Revenue and Volume Forecast, by Patient Group
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Drug Type
13.2.14.2. Market Revenue and Volume Forecast, by Formulation
13.2.14.3. Market Revenue and Volume Forecast, by Route of Administration
13.2.14.4. Market Revenue and Volume Forecast, by Distribution Channel
13.2.15. Market Revenue and Volume Forecast, by Patient Group
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Drug Type
13.3.2. Market Revenue and Volume Forecast, by Formulation
13.3.3. Market Revenue and Volume Forecast, by Route of Administration
13.3.4. Market Revenue and Volume Forecast, by Distribution Channel
13.3.5. Market Revenue and Volume Forecast, by Patient Group
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Drug Type
13.3.6.2. Market Revenue and Volume Forecast, by Formulation
13.3.6.3. Market Revenue and Volume Forecast, by Route of Administration
13.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.3.7. Market Revenue and Volume Forecast, by Patient Group
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Drug Type
13.3.8.2. Market Revenue and Volume Forecast, by Formulation
13.3.8.3. Market Revenue and Volume Forecast, by Route of Administration
13.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel
13.3.9. Market Revenue and Volume Forecast, by Patient Group
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Drug Type
13.3.10.2. Market Revenue and Volume Forecast, by Formulation
13.3.10.3. Market Revenue and Volume Forecast, by Route of Administration
13.3.10.4. Market Revenue and Volume Forecast, by Distribution Channel
13.3.10.5. Market Revenue and Volume Forecast, by Patient Group
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Drug Type
13.3.11.2. Market Revenue and Volume Forecast, by Formulation
13.3.11.3. Market Revenue and Volume Forecast, by Route of Administration
13.3.11.4. Market Revenue and Volume Forecast, by Distribution Channel
13.3.11.5. Market Revenue and Volume Forecast, by Patient Group
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Drug Type
13.4.2. Market Revenue and Volume Forecast, by Formulation
13.4.3. Market Revenue and Volume Forecast, by Route of Administration
13.4.4. Market Revenue and Volume Forecast, by Distribution Channel
13.4.5. Market Revenue and Volume Forecast, by Patient Group
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Drug Type
13.4.6.2. Market Revenue and Volume Forecast, by Formulation
13.4.6.3. Market Revenue and Volume Forecast, by Route of Administration
13.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.4.7. Market Revenue and Volume Forecast, by Patient Group
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Drug Type
13.4.8.2. Market Revenue and Volume Forecast, by Formulation
13.4.8.3. Market Revenue and Volume Forecast, by Route of Administration
13.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel
13.4.9. Market Revenue and Volume Forecast, by Patient Group
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Drug Type
13.4.10.2. Market Revenue and Volume Forecast, by Formulation
13.4.10.3. Market Revenue and Volume Forecast, by Route of Administration
13.4.10.4. Market Revenue and Volume Forecast, by Distribution Channel
13.4.10.5. Market Revenue and Volume Forecast, by Patient Group
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Drug Type
13.4.11.2. Market Revenue and Volume Forecast, by Formulation
13.4.11.3. Market Revenue and Volume Forecast, by Route of Administration
13.4.11.4. Market Revenue and Volume Forecast, by Distribution Channel
13.4.11.5. Market Revenue and Volume Forecast, by Patient Group
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Drug Type
13.5.2. Market Revenue and Volume Forecast, by Formulation
13.5.3. Market Revenue and Volume Forecast, by Route of Administration
13.5.4. Market Revenue and Volume Forecast, by Distribution Channel
13.5.5. Market Revenue and Volume Forecast, by Patient Group
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Drug Type
13.5.6.2. Market Revenue and Volume Forecast, by Formulation
13.5.6.3. Market Revenue and Volume Forecast, by Route of Administration
13.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel
13.5.7. Market Revenue and Volume Forecast, by Patient Group
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Drug Type
13.5.8.2. Market Revenue and Volume Forecast, by Formulation
13.5.8.3. Market Revenue and Volume Forecast, by Route of Administration
13.5.8.4. Market Revenue and Volume Forecast, by Distribution Channel
13.5.8.5. Market Revenue and Volume Forecast, by Patient Group
14.1. Roche Holding AG (Xenical)
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. GlaxoSmithKline plc (Alli)
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Alizyme Therapeutics (Cetilistat developer)
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Mylan N.V. (now Viatris)
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Cipla Ltd.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Eisai Co., Ltd.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Boehringer Ingelheim (research-based obesity targets)
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. LG Chem (obesity pipeline)
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Currax Pharmaceuticals (alli distribution in U.S.)
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Hisamitsu Pharmaceutical (transdermal R&D)
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description